INBS reports FY2026 revenue up 38% to $4.2M; gross margin expands to 48.63%

INTELLIGENT BIO SOLUTIONS INC.

2026-FY EPS reported -$8.44 revenue$4,215,175

FY2026 revenue $4.2M, up 38% YoY from $3.05M; gross profit $2.05M, up 64% YoY.
Gross margin 48.63%, up 778 bps from 40.85%; driven by Syrma Johari manufacturing transition.
Reader installed base 1,886 units (+22% YoY); consumable cartridges 106,500 (+35%); 502 active customers.
FDA 510(k) submission on track for H2 calendar 2026; all clinical data collection completed.
New strategic partnership with Bouygues UK for drug-testing rollout; eighth European patent granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.